Amphastar Pharmaceuticals, Inc. (AMPH)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Revenues | 174,414 | 170,528 | 191,214 | |
| Cost of revenues | 87,924 | 85,277 | 89,273 | |
| Gross profit | 86,490 | 85,251 | 101,941 | |
| Selling, distribution, and marketing | 10,235 | 11,866 | 8,995 | |
| Research and development | 20,080 | 20,096 | 21,077 | |
| General and administrative | 13,991 | 15,996 | 14,821 | |
| Total operating expenses | 44,306 | 47,958 | 44,893 | |
| Income from operations | 42,184 | 37,293 | 57,048 | |
| Other income (expenses), net | 1,511 | -2,234 | -5,094 | |
| Interest income | 1,921 | 2,089 | 2,427 | |
| Interest expense | 6,281 | 6,286 | 6,698 | |
| Total non-operating income (expenses), net | -2,849 | -6,431 | -9,365 | |
| Income before income taxes | 39,335 | 30,862 | 47,683 | |
| Income tax provision | 8,305 | 5,577 | 7,254 | |
| Income before equity in losses of unconsolidated affiliate | 31,030 | 25,285 | 40,429 | |
| Net income attributable to amphastar pharmaceuticals, inc | - | 25,285 | - | |
| Net income | 31,030 | 25,285 | 40,429 | |
| Earnings per share, basic | 0.66 | 0.53 | 0.83 | |
| Earnings per share, diluted | 0.64 | 0.51 | 0.78 | |
| Weighted average number of shares outstanding, basic | 46,949,000 | 47,641,000 | 48,621,000 | |
| Weighted average number of shares outstanding, diluted | 48,128,000 | 49,890,000 | 51,862,000 | |